Houston medtech accelerator announces inaugural cohort

future of health care

Five companies have been selected for a brand new accelerator program in Houston. Image via Getty Images

A Houston medical technology organization has announced the inaugural cohort of a new early-stage accelerator.

M1 MedTech, launched this year by Houston-based Proxima Clinical Research, announced its Fall 2022 cohort.

“This initial cohort launches M1 MedTech with an interactive 14-week agenda covering the basics every emerging MedTech business needs to progress from a startup to an established solution in their market,” says Sean Bittner, director of programs at M1 MedTech, in a news release.

The accelerator will equip early-stage startups with storytelling, business plan support, investor connections, FDA guidance, research, and more through one-on-one consultations, workships, and in-kind services.

The first cohort includes five startups, per the release from the company:

  1. Linovasc. Providing a long overdue major update to balloon angioplasty devices in over 50 years, the Linovasc solution offers a safer branch occlusion and aortic stent dilatation using a toroidal balloon that expands the aorta uniformly without the ischemia caused by current treatments. The company is founded by Bruce Addis.
  2. Grapheton. Founded by Sam Kassegne and Bao Nguyen, Grapheton's patented carbon materials work with electrically active devices to improve the longevity and outcome of bioelectric implants in the body. Terry Lingren serves as the CEO of the startup.
    • Rhythio Medical. Founded by Kunal Shah and Savannah Esteve, Rhythio is the first preventative approach to heart arrhythmias.The chief medical officer is Dr. Mehdi Razavi.
      • PONS Technology. An AI cognitive functioning ultrasound device attempting to change the way ultrasound is done, PONS is founded by CEO: Soner Haci and CTO: Ilker Hacihaliloglu.
        • Vivifi Medical. Founded by CEO Tushar Sharma, Vivifi is the first suture-less laparoscopic technology that connects vessels to improve male infertility and benign prostatic hyperplasia. The company's senior R&D engineer is Frida Montoya.

          The program includes support from sponsors and experts from: Proxima Clinical Research, Greenlight Guru, Medrio, Galen Data, Merge Medical Device Studio, Venn Negotiation, Engagement PR & Marketing, Aleberry Creative, and others.

          “This is an amazing opportunity for emerging founders to learn the progression of pipelining their ideas through the FDA and absorb the critical strategies for success early in their business development,” says Isabella Schmitt, principal at M1 MedTech and director of regulatory affairs at Proxima CRO, in the release.

          MassChallenge has selected 10 Houston startups to participate in its 2022 United States cohort. Photo courtesy of MassChallenge

          MassChallenge names 10 Houston companies to national cohort

          class of 2022

          Ten Houston companies have been chosen for MassChallenge’s 2022 United States cohort of early-stage startups.

          The 10 Houston startups are:

          • BEMY Cosmetics, a maker of skin rejuvenation products based on RNA technology
          • Eisana Corp., whose products are designed to ease the side effects of breast cancer treatment
          • Enrichly, a self-esteem-based e-learning platform and gaming app
          • RE.STATEMENT, an online marketplace for upcycled clothing
          • Roxie Health, a virtual medical assigned geared toward preventing falls by seniors
          • Vivifi Medical, whose laparoscopic technology treats male infertility and prostate gland enlargement
          • Vouchpad, a provider of affordable student loans
          • Equiliberty, an equitable fintech platform focused on creating generational wealth
          • National Police Data, an organization creating an index of Police data in America
          • Cryodesalination, a new low cost desalination process focused on providing access to fresh water

          In all, the MassChallenge innovation network selected 250 early-stage startups for this fall’s U.S. accelerator program in Houston, Austin, Dallas, Boston, and Providence, Rhode Island. Participants are eligible for equity-free cash prizes of as much as $1 million. MassChallenge is open to early-stage startups that have raised less than $1 million in equity funding and have generated less than $2 million in revenue over the past 12 months.

          “We’re in the business of solving massive challenges, and to do that, we must continue to support diverse founders with bold ideas across geographies, industry verticals, and demographics in creative ways that allow them to wholly own their ideas and solve some of our world’s most pressing problems,” Hope Hopkins, head of acceleration at MassChallenge, says in a news release.

          This year’s cohort will have access to MassChallenge’s new residency program, which allows founder teams to travel to MassChallenge’s U.S.-based hubs. The residency program already is underway in Houston and Boston.

          In addition, founders will be able to take advantage of a newly created program that enables them to connect with MassChallenge stakeholders.

          Last year, MassChallenge named 71 startups to its Houston cohort, and several walked away from the program with cash prizes. Per the nonprofit's website, there isn't a Houston-specific program planned for 2022. MassChallenge has had a presence in Houston since January of 2019 when it announced the Bayou City as a new market.

          Note: This article originally identified seven Houston startups. The article has been updated to include the three Houston startups initially omitted.

          Houston's medical innovation community congregated to discuss breakthrough innovations in health care. Photo via Getty Images

          Houston organizations announce 10 most promising life science startups

          future of health care

          What startups are creating the future of health care? A Houston conference this week gathered to discuss.

          The 10th annual Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship engaged thought leadership within the life science community with panels, discussions, and more. Additionally, 49 companies pitched their solutions across medical device, therapeutics, pharmaceuticals, and more to the crowd.

          Austin-based Dynamic Light won the Michael E. DeBakey Memorial Life Science Award, established by BioHouston in honor of the groundbreaking Houston cardiovascular surgeon. The software company integrates with microscope or robotic systems to provide better visuals to surgeons and health care providers and reduce medical errors, radiation and costs. The award was presented by Ann Tanabe, CEO of BioHouston.

          The event also named the 10 most promising life science companies selected by investors and presented by the Greater Houston Partnership. This year's selection included the following companies, in alphabetical order.

          Ares Immunotherapy

          Photo via Getty Images

          Based in Cartersville, Georgia, Ares Immunotherapy uses a unique subset of T-cells for the treatment of solid tumors. According to the company, it is is preparing for a first in man trial in mesothelioma in 2023.

          Corveus Medical

          Photo courtesy of TMC

          Houston-based Corveus Medical, which was formerly known as Caridian Medical, is a part of TMC's Biodesign program. The company was founded by Ishan Kamat, COO, and Tyler Melton, CEO.

          "We are developing a novel, catheter-based device that performs a targeted sympathetic nerve ablation to treat heart failure," according to the company. "Our solution leverages the body’s natural mechanisms to bring fluid levels back to normal, giving physicians an effective treatment option, reducing costs for hospitals, and improving quality of life for the patient."

          Drusolv Therapeutics

          Photo via Pexels

          Drusolv Therapeutics, based in Philadelphia, Pennsylvania, was founded out of Harvard University and been validated in a proof-of-concept clinical trial. The company's product, a novel reformulation of atorvastatin, is targeting age-related macular degeneration, or AMD, a serious eye disease. According to the company, it's a $4 billion a year, unmet need.

          EMPIRI

          Photo via jlabs.jnjinnovation.com

          Houston-based EMPIRI is an early-stage biotechnology company currently focusing on precision oncology and utilizing automation for personal diagnosis. The company works out of JLABS @ TMC.

          "Our proprietary 3D tissue culture method, E-slices, enables personalized drug response measurements from intact patient tissues," per the company. "E-slice has been clinically validated to accurately predict individual cancer patient responses to chemotherapies, targeted therapies, a immunotherapies."

          Lapovations

          Photo via Getty Images

          Based in Fayetteville, Arkansas, Lapovations is working on technologies that improve laparoscopy.

          "Our flagship product AbGrab is a single-use device that uses suction to lift the abdominal wall prior to closed insertion entry," according to the company. "Manually lifting can be difficult and unreliable, especially with obese patients or for clinicians with small hands."

          Maxwell Biosciences

          Photo by Chokniti Khongchum from Pexels

          Austin-based Maxwell Biosciences is creating anti-infectives that inactivate a broad spectrum of viruses. The company's product, CLAROMERS, has seen success in its preclinical animal studies, as well as lab-grown human tissues. Maxwell is fueled by over $30 million in non-dilutive and government funding (e.g. DARPA, NIH, NIAID).

          NeuraStasis

          Image via neurastasis.com

          Doctors have to respond quickly when treating ischemic stroke patients, and Houston-based NeuraStasis is working on a way to give them more time. Each minute a patient is waiting, irreparable damage is being done. The company's noninvasive solution uses electrical neurostimulation to preserve brain functionality. NeuraStasis is based in JLABS @ TMC.

          Vena Medical

          Image via venamed.ca

          Canada medical device company Vena Medical is working on the "world's smallest camera" that is able to record inside veins and arteries to help physicians treat stroke.

          Vivifi Medical

          Photo courtesy of TMC

          Houston-based Vivifi Medical, a Texas Medical Center Innovation company, is working to improve the quality of life of patients with Male Infertility and benign prostatic hyperplasia — 12 million men in the United States alone — by ending recurrency via suture-less laparoscopic technology.

          XN Health

          Image via xn-health.com

          XN Health, based in Houston, has developed a novel approach to phrenic nerve stimulation to treat progression of ventilator induced diaphragm disfunction to help wean patients off the ventilator faster. The technology should speed up patient liberation times, shortening ICU stay, improve healthcare outcomes, and reduce health care costs.

          Ad Placement 300x100
          Ad Placement 300x600

          CultureMap Emails are Awesome

          Property Showcase

          Houston Intercontinental Airport's innovative upgrades ready for takeoff

          coming soon

          After almost five years of construction, passengers heading out of Bush Intercontinental Airport on October 22 will be the very first to experience the expanded, upgraded, and stylish Terminal D-West Pier, an expansion of the existing Terminal D.

          The new terminal is part of a broader initiative, the IAH Terminal Redevelopment Program (ITRP), a $1.458 billion project aimed at modernizing the airport's international travel capabilities. ITRP is the single largest capital improvement project developed by Houston Airports and include the refresh of the existing Terminal D, completed in 2023; the expansion of Terminal D with a new D-West Pier, which will be completed this fall 2024; and a new International Central Processor, slated for winter of 2024 and summer of 2025. More than 3,000 people spent more than one million hours on the construction project.

          Terminal D-West Pier features six new gates — D1 through D6 — that can simultaneously accommodate wide-body aircraft or converted to accommodate 10 narrow-body airplanes. The expanded terminal with its new capabilities supports increasing demand from passengers and airlines and should enhance the overall travel experience.

          The new terminal is part of a broader initiative, the IAH Terminal Redevelopment Program (ITRP), a $1.458 billion project aimed at modernizing the airport's international travel capabilities. Photo courtesy of Houston Airports

          In addition to adding 160,000-square-feet, the new wing also boasts eight new, Houston-inspired works by local artists. Those kind of details are why the Houston airport system won Best Airport Art & Entertainment Program in the prestigious Skytrax awards.

          The airport's 250 newly-hired employees will work among 16 new retail and dining concessions concepts in the Terminal D-West Pier. Passengers can dine at Houston Supply Co., which opened last month. Local restaurants The Kitchen and The Annie, along with popular national brands Popeyes, Einstein Bros. Bagels, Jamba Juice, Be Relax, Jetero Market, Semi-Sweet Confectionary, and a Lego Store will open for business on October 22.

          The new wing also boasts eight new, Houston-inspired works by local artists. Photo courtesy of Houston Airports

          "We are focused on improving the overall passenger experience at the airport — from parking and traffic to providing modern terminals with the right amenities. This project is a major investment in our city's future," Houston Mayor John Whitmire said in a statement. "The newly expanded international terminal enhances Houston's reputation as a world-class city and provides a boost to our economy, supporting jobs and attracting more visitors from around the globe."

          The new terminal offers a host of other amenities designed to make passengers' experiences more comfortable. They include a mother's room, a sensory room, a child's play area, and expanded men's, women's, and family restrooms. The restrooms utilize smart technology sensors that trigger soap and water. Door locks alert to whether a restroom stall is vacant or occupied and soft LED lighting accentuates floor-to-ceiling photography spotlighting Houston's natural beauty.

          The new wing has 16 new retail and dining concessions concepts. Photo courtesy of Houston Airports

          An International Arrivals corridor provides views of the airfield, the concourse, and large-scale photography inspired by Houston.

          More than 500 modern and comfortable seats, including chairs, cushioned benches, and cozy loungers, featuring cup holders and charging capabilities, are present inside the terminal.

          "We are excited to share this milestone with the residents of Houston," said Jim Szczesniak, director of aviation for Houston Airports. "The opening of the Terminal D-West Pier is a testament to the hard work and dedication of our team and our partners. This world-class facility will provide a seamless and efficient travel experience for millions of passengers each year. The new pier will provide the necessary capacity so that Houston can continue to attract more nonstop flights to cities around the globe."

          New features include a mother's room, a sensory room, a child's play area, and expanded men's, women's, and family restrooms. Photo courtesy of Houston Airports

          ------

          This article originally ran on CultureMap.

          12 health tech startups named to Houston accelerator's next bootcamp

          onboarding

          Twelve promising health tech startups have been selected for the annual bootcamp at the Texas Medical Center.

          TMC's Accelerator for HealthTech selected 12 companies from around the world and across specialties for the opportunity. Following the bootcamp, TMC will move forward a selection of startups to join its accelerator.

          "Houston, a thriving hub for innovation, is rapidly becoming the destination of choice for healthtech companies," reads a statement from TMC. "With the Texas Medical Center at its heart, the city offers unparalleled resources, cutting-edge research facilities, and a collaborative spirit that fosters growth. This environment not only attracts startups but also provides them with the necessary tools to navigate the complex landscape of healthcare commercialization."

          Through the bootcamp, the participants will engage with advisors and industry experts, refine their business models, prepare for market entry, and have opportunities for collaboration with the TMC's member organizations.

          The selected bootcamp companies, according to TMC, include:

          • Alyf, founded in Newport Beach, California, has developed a personalized cardiac care system that brings patients and providers together with real-time, AI-driven insights, enabling them to monitor, track, and improve cardiac health outcomes collaboratively.
          • Seoul, South Korea-based Deepmetrics leverages artificial intelligence to provide ICU smart care services that optimize medical device settings, such as mechanical ventilators, to reduce mortality and shorten the length of stay for critically ill patients worldwide.
          • EquityQuotient, from New York City, is a healthcare intelligence platform that automates compliance and provides actionable insights by aggregating public, private, and first-party data, using proprietary analytics to help leaders address disparities, improve outcomes, and lower care costs.
          • Also from New York City, Ethermed's AI-powered solution streamlines prior authorizations, eliminating up to 90 percent of auths and 70 percent of the labor involved. Ethermed requires no workflow changes, is fully auditable, and offers aligned incentives from a mission-driven, human-focused company.
          • Fibricheck, based in Hasselt, Belgium, transforms ordinary smartphones into regulated digital heart rhythm monitors, offering unparalleled access to cardiovascular diagnostics for patients and streamlined workflows for physicians.
          • Austin-based NearWave has developed a non-invasive, AI-powered handheld imaging device that can predict breast cancer therapy response within seven days.
          • Pragmaclin, founded in Newfoundland, Canada, developed a cutting-edge PRIMS (Parkinson’s Remote Interactive Management System) that leverages depth cameras and machine learning to monitor and assess Parkinson’s Disease symptoms, offering healthcare professionals remote and in-clinic insights to enhance treatment decisions.
          • Somnair, a Baltimore, Maryland, company, is developing a non-invasive neurostimulation oral appliance for treating obstructive sleep apnea, offering a sleek, retainer-sized device that provides an effective alternative to CPAP or invasive surgery for millions of patients.
          • Vancouver, Canada-headquartered Total Flow Medical is developing solutions to enhance the quality of care and life for patients requiring the use of a heart-lung machine during surgery or life support.
          • Tympulse, hailing from Dublin, Ireland, is commercializing TympanoColl, an innovative and disruptive solution for eardrum (Tympanic Membrane) repair in an outpatient setting through the ear canal.
          • Perth, Australia-based Vital Trace is developing a continuous lactate monitor for real-time, accurate detection of fetal distress.
          • New York City's WorkUp is a healthcare-specific talent pipeline management platform that connects students with tailored resources for their clinical career journey, providing personalized support as their needs evolve.

          University of Houston-founded company secures $2.5M in NIH grant funding

          all in the timing

          You could say that the booming success of Houston biotech company CellChorus owes very much to auspicious TIMING. Those six letters stand for Time-lapse Imaging Microscopy In Nanowell Grids, a platform for dynamic single-cell analysis.

          This week, CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding from the National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health. A $350,000 Phase I grant is already underway. Once predetermined milestones are achieved, this will lead to a two-year $2.1 million Phase II grant.

          The TIMING platform was created by UH Single Cell Lab researchers Navin Varadarajan and Badri Roysam. TIMING generates high-throughput in-vitro assays that quantitatively profile interactions between cells on a large scale, particularly what happens when immune cells confront target cells. This has been especially useful in the realm of immuno-oncology, where it has demonstrated its power in designing novel therapies, selecting lead candidates for clinical trials and evaluating the potency of manufactured cells.

          “By combining AI, microscale manufacturing and advanced microscopy, the TIMING platform yields deep insight into cellular behaviors that directly impact human disease and new classes of therapeutics,” says Rebecca Berdeaux, chief scientific officer at CellChorus. “The generous support of NCATS enables our development of computational tools that will ultimately integrate single-cell dynamic functional analysis of cell behavior with intracellular signaling events.”

          Houston’s CellChorus Innovation Lab supports both the further development of TIMING and projects for early-access customers. Those customers include top-25 biopharmaceutical companies, venture-backed biotechnology companies, a leading comprehensive cancer center and a top pediatric hospital, says CEO Daniel Meyer.

          CellChorus’s publications include papers written in collaboration with researchers from the Baylor College of Medicine, Houston Methodist, MD Anderson, Texas Children’s Hospital, the University of Texas and UTHealth in journals including Nature Cancer, Journal of Clinical Investigation and The Journal for ImmunoTherapy of Cancer.

          The new Small Business Technology Transfer (STTR) award will specifically support the development of a scalable integrated software system conceived with the goal of analyzing cells that are not fluorescently labeled. This label-free analysis will be based on new AI and machine learning (ML) models trained on tens of millions of images of cells.

          “This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” says Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”

          The Houston-born-and-bred company couldn’t have a more appropriate home, says Meyer.

          “Houston is a premier location for clinical care and the development of biotechnology and life sciences technologies. In particular, Houston has established itself as a leader in the development and delivery of immune cell-based therapies,” the CEO explains. “As a spin-out from the Single Cell Lab at the University of Houston, we benefit from working with world-class experts at local institutions.”

          In May, the company received a similar $2.5 million SBIR grant from NCATS at the NIH. Also this summer, CellChorus's technology was featured in Nature Cancer.

          View All Listings